ATUM's headquarters in Newark, California.
ATUM has announced the launch of its CHO-K1-derived discoCHO cell line for transient protein production. The new solution aims to allow for robust transient therapeutic protein expression while expressing similar critical quality attributes as those from a stable CHO-K1 manufacturing cell line, miCHO-GS.
CHO-K1 cells are used in the manufacturing of protein-based biologics due to their dominant cell line. However, traditionally CHO-K1-derived cells generate low protein yields in early discovery processes. This issue leads to HEK cell lines often being utilised in this stage as they tend to generate the required protein quantities for evaluation. However, HEK platforms express antibodies with critical quality attributes (CQA) that don’t match the final CHO-K1-derived manufacturing cell line, leading to unpredictable protein characteristics.
ATUM’s new launch is set to provide a fast, productive, and predictable ecosystem combating the previously mentioned issues. The company has accomplished this by combining ATUM’s pre-existing miCHO-GS cell line with the CHO-K1-derived discoCHO for robust transient productivity.
“The introduction of discoCHO for antibody production enhances our industry-leading ecosystem, providing our customers with an exceptionally efficient and consistent process to bring drugs to market faster while minimising risks,” said Jeremy Minshull, PhD, Co-Founder and CEO of ATUM.
Following the launch, ATUM will be able to provide its customers with integrated pipeline support along all steps.